nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—CYP3A4—type 2 diabetes mellitus	0.256	1	CbGaD
Darifenacin—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.0394	0.101	CbGbCtD
Darifenacin—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0388	0.0998	CbGbCtD
Darifenacin—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.0363	0.0934	CbGbCtD
Darifenacin—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0346	0.089	CbGbCtD
Darifenacin—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0317	0.0814	CbGbCtD
Darifenacin—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.0298	0.0767	CbGbCtD
Darifenacin—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.0286	0.0735	CbGbCtD
Darifenacin—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.0277	0.0711	CbGbCtD
Darifenacin—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.025	0.0643	CbGbCtD
Darifenacin—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.019	0.0488	CbGbCtD
Darifenacin—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0182	0.0467	CbGbCtD
Darifenacin—CYP3A4—Orlistat—type 2 diabetes mellitus	0.0182	0.0467	CbGbCtD
Darifenacin—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.0172	0.0442	CbGbCtD
Darifenacin—CYP3A4—Glyburide—type 2 diabetes mellitus	0.0128	0.0329	CbGbCtD
Darifenacin—CYP3A4—Losartan—type 2 diabetes mellitus	0.0117	0.0301	CbGbCtD
Darifenacin—Clotrimazole—CYP11A1—type 2 diabetes mellitus	0.000711	0.234	CrCbGaD
Darifenacin—Loperamide—CALM1—type 2 diabetes mellitus	0.000683	0.225	CrCbGaD
Darifenacin—Clotrimazole—ABCC2—type 2 diabetes mellitus	0.000391	0.129	CrCbGaD
Darifenacin—Clotrimazole—CYP2E1—type 2 diabetes mellitus	0.000274	0.0903	CrCbGaD
Darifenacin—Clotrimazole—CYP1A2—type 2 diabetes mellitus	0.000261	0.0859	CrCbGaD
Darifenacin—Infection—Valsartan—type 2 diabetes mellitus	0.000219	0.000867	CcSEcCtD
Darifenacin—Rash—Glipizide—type 2 diabetes mellitus	0.000219	0.000867	CcSEcCtD
Darifenacin—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000218	0.000866	CcSEcCtD
Darifenacin—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000218	0.000866	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	0.000218	0.000866	CcSEcCtD
Darifenacin—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.000218	0.000865	CcSEcCtD
Darifenacin—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.000218	0.000863	CcSEcCtD
Darifenacin—Oedema—Orlistat—type 2 diabetes mellitus	0.000218	0.000863	CcSEcCtD
Darifenacin—Headache—Glipizide—type 2 diabetes mellitus	0.000217	0.000861	CcSEcCtD
Darifenacin—Palpitations—Metformin—type 2 diabetes mellitus	0.000217	0.000861	CcSEcCtD
Darifenacin—Insomnia—Gliclazide—type 2 diabetes mellitus	0.000217	0.000859	CcSEcCtD
Darifenacin—Shock—Valsartan—type 2 diabetes mellitus	0.000217	0.000859	CcSEcCtD
Darifenacin—Infection—Orlistat—type 2 diabetes mellitus	0.000216	0.000857	CcSEcCtD
Darifenacin—Loss of consciousness—Metformin—type 2 diabetes mellitus	0.000216	0.000856	CcSEcCtD
Darifenacin—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000216	0.000856	CcSEcCtD
Darifenacin—Flatulence—Losartan—type 2 diabetes mellitus	0.000215	0.000852	CcSEcCtD
Darifenacin—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000214	0.000848	CcSEcCtD
Darifenacin—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000214	0.000848	CcSEcCtD
Darifenacin—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000214	0.000847	CcSEcCtD
Darifenacin—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000214	0.000847	CcSEcCtD
Darifenacin—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000213	0.000846	CcSEcCtD
Darifenacin—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000213	0.000846	CcSEcCtD
Darifenacin—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000213	0.000845	CcSEcCtD
Darifenacin—Hypertension—Metformin—type 2 diabetes mellitus	0.000212	0.000841	CcSEcCtD
Darifenacin—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000212	0.00084	CcSEcCtD
Darifenacin—Oedema peripheral—Ramipril—type 2 diabetes mellitus	0.000212	0.000839	CcSEcCtD
Darifenacin—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000211	0.000838	CcSEcCtD
Darifenacin—Back pain—Losartan—type 2 diabetes mellitus	0.000211	0.000837	CcSEcCtD
Darifenacin—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000211	0.000836	CcSEcCtD
Darifenacin—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.000211	0.000836	CcSEcCtD
Darifenacin—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	0.00021	0.000834	CcSEcCtD
Darifenacin—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000209	0.00083	CcSEcCtD
Darifenacin—Headache—Pioglitazone—type 2 diabetes mellitus	0.000208	0.000825	CcSEcCtD
Darifenacin—Syncope—Irbesartan—type 2 diabetes mellitus	0.000208	0.000824	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000208	0.000823	CcSEcCtD
Darifenacin—Visual impairment—Ramipril—type 2 diabetes mellitus	0.000207	0.000821	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000207	0.00082	CcSEcCtD
Darifenacin—Nausea—Glipizide—type 2 diabetes mellitus	0.000206	0.000817	CcSEcCtD
Darifenacin—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000206	0.000816	CcSEcCtD
Darifenacin—Vision blurred—Losartan—type 2 diabetes mellitus	0.000206	0.000815	CcSEcCtD
Darifenacin—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000205	0.000813	CcSEcCtD
Darifenacin—Pain—Gliclazide—type 2 diabetes mellitus	0.000205	0.000812	CcSEcCtD
Darifenacin—Constipation—Gliclazide—type 2 diabetes mellitus	0.000205	0.000812	CcSEcCtD
Darifenacin—Rash—Glimepiride—type 2 diabetes mellitus	0.000204	0.000809	CcSEcCtD
Darifenacin—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000204	0.000808	CcSEcCtD
Darifenacin—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	0.000204	0.000808	CcSEcCtD
Darifenacin—Rash—Sitagliptin—type 2 diabetes mellitus	0.000203	0.000806	CcSEcCtD
Darifenacin—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000203	0.000806	CcSEcCtD
Darifenacin—Erythema multiforme—Ramipril—type 2 diabetes mellitus	0.000203	0.000806	CcSEcCtD
Darifenacin—Headache—Glimepiride—type 2 diabetes mellitus	0.000203	0.000804	CcSEcCtD
Darifenacin—Cough—Irbesartan—type 2 diabetes mellitus	0.000202	0.000802	CcSEcCtD
Darifenacin—Headache—Sitagliptin—type 2 diabetes mellitus	0.000202	0.000801	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000201	0.000795	CcSEcCtD
Darifenacin—Oedema—Metformin—type 2 diabetes mellitus	0.000201	0.000795	CcSEcCtD
Darifenacin—Hypertension—Irbesartan—type 2 diabetes mellitus	0.0002	0.000794	CcSEcCtD
Darifenacin—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.0002	0.000792	CcSEcCtD
Darifenacin—Angioedema—Losartan—type 2 diabetes mellitus	0.000199	0.00079	CcSEcCtD
Darifenacin—Infection—Metformin—type 2 diabetes mellitus	0.000199	0.00079	CcSEcCtD
Darifenacin—Insomnia—Valsartan—type 2 diabetes mellitus	0.000199	0.000789	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000198	0.000786	CcSEcCtD
Darifenacin—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000197	0.000783	CcSEcCtD
Darifenacin—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000197	0.000783	CcSEcCtD
Darifenacin—Shock—Metformin—type 2 diabetes mellitus	0.000197	0.000782	CcSEcCtD
Darifenacin—Insomnia—Orlistat—type 2 diabetes mellitus	0.000197	0.00078	CcSEcCtD
Darifenacin—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000197	0.00078	CcSEcCtD
Darifenacin—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000197	0.00078	CcSEcCtD
Darifenacin—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000196	0.000778	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000196	0.000777	CcSEcCtD
Darifenacin—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000196	0.000777	CcSEcCtD
Darifenacin—Somnolence—Valsartan—type 2 diabetes mellitus	0.000196	0.000776	CcSEcCtD
Darifenacin—Syncope—Losartan—type 2 diabetes mellitus	0.000196	0.000776	CcSEcCtD
Darifenacin—Skin disorder—Metformin—type 2 diabetes mellitus	0.000195	0.000772	CcSEcCtD
Darifenacin—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000194	0.000768	CcSEcCtD
Darifenacin—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000194	0.000768	CcSEcCtD
Darifenacin—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000194	0.000768	CcSEcCtD
Darifenacin—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000193	0.000765	CcSEcCtD
Darifenacin—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000193	0.000765	CcSEcCtD
Darifenacin—Palpitations—Losartan—type 2 diabetes mellitus	0.000193	0.000764	CcSEcCtD
Darifenacin—Nausea—Glimepiride—type 2 diabetes mellitus	0.000192	0.000762	CcSEcCtD
Darifenacin—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000192	0.00076	CcSEcCtD
Darifenacin—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000192	0.00076	CcSEcCtD
Darifenacin—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000192	0.000759	CcSEcCtD
Darifenacin—Asthenia—Glyburide—type 2 diabetes mellitus	0.000191	0.000759	CcSEcCtD
Darifenacin—Cough—Losartan—type 2 diabetes mellitus	0.00019	0.000755	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.00019	0.000754	CcSEcCtD
Darifenacin—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000189	0.000751	CcSEcCtD
Darifenacin—Oedema—Irbesartan—type 2 diabetes mellitus	0.000189	0.00075	CcSEcCtD
Darifenacin—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000189	0.00075	CcSEcCtD
Darifenacin—Pruritus—Glyburide—type 2 diabetes mellitus	0.000189	0.000749	CcSEcCtD
Darifenacin—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000188	0.000746	CcSEcCtD
Darifenacin—Constipation—Valsartan—type 2 diabetes mellitus	0.000188	0.000746	CcSEcCtD
Darifenacin—Infection—Irbesartan—type 2 diabetes mellitus	0.000188	0.000745	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000188	0.000745	CcSEcCtD
Darifenacin—Shock—Irbesartan—type 2 diabetes mellitus	0.000186	0.000738	CcSEcCtD
Darifenacin—Pain—Orlistat—type 2 diabetes mellitus	0.000186	0.000738	CcSEcCtD
Darifenacin—Arthralgia—Losartan—type 2 diabetes mellitus	0.000186	0.000736	CcSEcCtD
Darifenacin—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000186	0.000736	CcSEcCtD
Darifenacin—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000186	0.000736	CcSEcCtD
Darifenacin—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000185	0.000732	CcSEcCtD
Darifenacin—Rash—Bromocriptine—type 2 diabetes mellitus	0.000184	0.00073	CcSEcCtD
Darifenacin—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000184	0.000729	CcSEcCtD
Darifenacin—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000184	0.000729	CcSEcCtD
Darifenacin—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000183	0.000726	CcSEcCtD
Darifenacin—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000183	0.000725	CcSEcCtD
Darifenacin—Headache—Bromocriptine—type 2 diabetes mellitus	0.000183	0.000725	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000183	0.000724	CcSEcCtD
Darifenacin—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000183	0.000724	CcSEcCtD
Darifenacin—Dry mouth—Losartan—type 2 diabetes mellitus	0.000182	0.00072	CcSEcCtD
Darifenacin—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.00018	0.000714	CcSEcCtD
Darifenacin—Confusional state—Losartan—type 2 diabetes mellitus	0.00018	0.000712	CcSEcCtD
Darifenacin—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000179	0.000711	CcSEcCtD
Darifenacin—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000179	0.000709	CcSEcCtD
Darifenacin—Somnolence—Metformin—type 2 diabetes mellitus	0.000178	0.000707	CcSEcCtD
Darifenacin—Oedema—Losartan—type 2 diabetes mellitus	0.000178	0.000706	CcSEcCtD
Darifenacin—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000178	0.000706	CcSEcCtD
Darifenacin—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000178	0.000705	CcSEcCtD
Darifenacin—Infection—Losartan—type 2 diabetes mellitus	0.000177	0.000701	CcSEcCtD
Darifenacin—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000177	0.0007	CcSEcCtD
Darifenacin—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000176	0.0007	CcSEcCtD
Darifenacin—Shock—Losartan—type 2 diabetes mellitus	0.000175	0.000695	CcSEcCtD
Darifenacin—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000175	0.000692	CcSEcCtD
Darifenacin—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000174	0.00069	CcSEcCtD
Darifenacin—Tachycardia—Losartan—type 2 diabetes mellitus	0.000174	0.000689	CcSEcCtD
Darifenacin—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000173	0.000687	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000173	0.000686	CcSEcCtD
Darifenacin—Clotrimazole—CYP3A4—type 2 diabetes mellitus	0.000173	0.0569	CrCbGaD
Darifenacin—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000172	0.000683	CcSEcCtD
Darifenacin—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.000172	0.000682	CcSEcCtD
Darifenacin—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000172	0.000682	CcSEcCtD
Darifenacin—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000172	0.000682	CcSEcCtD
Darifenacin—Constipation—Metformin—type 2 diabetes mellitus	0.000171	0.00068	CcSEcCtD
Darifenacin—Angioedema—Ramipril—type 2 diabetes mellitus	0.000171	0.000678	CcSEcCtD
Darifenacin—Vomiting—Glyburide—type 2 diabetes mellitus	0.00017	0.000673	CcSEcCtD
Darifenacin—Pruritus—Gliclazide—type 2 diabetes mellitus	0.00017	0.000672	CcSEcCtD
Darifenacin—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000169	0.000669	CcSEcCtD
Darifenacin—Rash—Glyburide—type 2 diabetes mellitus	0.000168	0.000667	CcSEcCtD
Darifenacin—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000168	0.000667	CcSEcCtD
Darifenacin—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000168	0.000667	CcSEcCtD
Darifenacin—Syncope—Ramipril—type 2 diabetes mellitus	0.000168	0.000665	CcSEcCtD
Darifenacin—Headache—Glyburide—type 2 diabetes mellitus	0.000167	0.000663	CcSEcCtD
Darifenacin—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000167	0.00066	CcSEcCtD
Darifenacin—Palpitations—Ramipril—type 2 diabetes mellitus	0.000165	0.000655	CcSEcCtD
Darifenacin—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000165	0.000655	CcSEcCtD
Darifenacin—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.000164	0.000652	CcSEcCtD
Darifenacin—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000164	0.00065	CcSEcCtD
Darifenacin—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000164	0.00065	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000163	0.000648	CcSEcCtD
Darifenacin—Cough—Ramipril—type 2 diabetes mellitus	0.000163	0.000647	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000162	0.000643	CcSEcCtD
Darifenacin—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000162	0.000643	CcSEcCtD
Darifenacin—Constipation—Irbesartan—type 2 diabetes mellitus	0.000162	0.000641	CcSEcCtD
Darifenacin—Pain—Irbesartan—type 2 diabetes mellitus	0.000162	0.000641	CcSEcCtD
Darifenacin—Insomnia—Losartan—type 2 diabetes mellitus	0.000161	0.000639	CcSEcCtD
Darifenacin—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.00016	0.000635	CcSEcCtD
Darifenacin—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000159	0.000631	CcSEcCtD
Darifenacin—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000159	0.000629	CcSEcCtD
Darifenacin—Nausea—Glyburide—type 2 diabetes mellitus	0.000159	0.000628	CcSEcCtD
Darifenacin—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000159	0.000628	CcSEcCtD
Darifenacin—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000158	0.000628	CcSEcCtD
Darifenacin—Somnolence—Losartan—type 2 diabetes mellitus	0.000158	0.000628	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000158	0.000627	CcSEcCtD
Darifenacin—Asthenia—Valsartan—type 2 diabetes mellitus	0.000158	0.000626	CcSEcCtD
Darifenacin—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000157	0.000621	CcSEcCtD
Darifenacin—Asthenia—Orlistat—type 2 diabetes mellitus	0.000156	0.000619	CcSEcCtD
Darifenacin—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000156	0.000618	CcSEcCtD
Darifenacin—Pruritus—Valsartan—type 2 diabetes mellitus	0.000156	0.000618	CcSEcCtD
Darifenacin—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000156	0.000618	CcSEcCtD
Darifenacin—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.000155	0.000613	CcSEcCtD
Darifenacin—Confusional state—Ramipril—type 2 diabetes mellitus	0.000154	0.00061	CcSEcCtD
Darifenacin—Pruritus—Orlistat—type 2 diabetes mellitus	0.000154	0.00061	CcSEcCtD
Darifenacin—Methadone—CYP1A2—type 2 diabetes mellitus	0.000153	0.0504	CrCbGaD
Darifenacin—Oedema—Ramipril—type 2 diabetes mellitus	0.000153	0.000605	CcSEcCtD
Darifenacin—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.000153	0.000605	CcSEcCtD
Darifenacin—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000152	0.000604	CcSEcCtD
Darifenacin—Constipation—Losartan—type 2 diabetes mellitus	0.000152	0.000604	CcSEcCtD
Darifenacin—Pain—Losartan—type 2 diabetes mellitus	0.000152	0.000604	CcSEcCtD
Darifenacin—Rash—Gliclazide—type 2 diabetes mellitus	0.000151	0.000599	CcSEcCtD
Darifenacin—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000151	0.000598	CcSEcCtD
Darifenacin—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000151	0.000597	CcSEcCtD
Darifenacin—Shock—Ramipril—type 2 diabetes mellitus	0.00015	0.000596	CcSEcCtD
Darifenacin—Headache—Gliclazide—type 2 diabetes mellitus	0.00015	0.000595	CcSEcCtD
Darifenacin—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.00015	0.000594	CcSEcCtD
Darifenacin—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.00015	0.000593	CcSEcCtD
Darifenacin—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000149	0.000591	CcSEcCtD
Darifenacin—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000149	0.00059	CcSEcCtD
Darifenacin—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000148	0.000588	CcSEcCtD
Darifenacin—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000148	0.000585	CcSEcCtD
Darifenacin—Fentanyl—CYP3A4—type 2 diabetes mellitus	0.000148	0.0486	CrCbGaD
Darifenacin—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.000147	0.000582	CcSEcCtD
Darifenacin—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.000146	0.000577	CcSEcCtD
Darifenacin—Dizziness—Valsartan—type 2 diabetes mellitus	0.000146	0.000577	CcSEcCtD
Darifenacin—Dizziness—Orlistat—type 2 diabetes mellitus	0.000144	0.00057	CcSEcCtD
Darifenacin—Asthenia—Metformin—type 2 diabetes mellitus	0.000144	0.00057	CcSEcCtD
Darifenacin—Nausea—Gliclazide—type 2 diabetes mellitus	0.000142	0.000564	CcSEcCtD
Darifenacin—Loperamide—CYP3A4—type 2 diabetes mellitus	0.000142	0.0468	CrCbGaD
Darifenacin—Pruritus—Metformin—type 2 diabetes mellitus	0.000142	0.000562	CcSEcCtD
Darifenacin—Abdominal pain—Losartan—type 2 diabetes mellitus	0.000141	0.000558	CcSEcCtD
Darifenacin—Vomiting—Valsartan—type 2 diabetes mellitus	0.00014	0.000555	CcSEcCtD
Darifenacin—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000139	0.000553	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.000139	0.000552	CcSEcCtD
Darifenacin—Rash—Valsartan—type 2 diabetes mellitus	0.000139	0.00055	CcSEcCtD
Darifenacin—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000139	0.00055	CcSEcCtD
Darifenacin—Vomiting—Orlistat—type 2 diabetes mellitus	0.000138	0.000548	CcSEcCtD
Darifenacin—Insomnia—Ramipril—type 2 diabetes mellitus	0.000138	0.000548	CcSEcCtD
Darifenacin—Headache—Valsartan—type 2 diabetes mellitus	0.000138	0.000547	CcSEcCtD
Darifenacin—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000137	0.000544	CcSEcCtD
Darifenacin—Rash—Orlistat—type 2 diabetes mellitus	0.000137	0.000544	CcSEcCtD
Darifenacin—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000137	0.000543	CcSEcCtD
Darifenacin—Headache—Orlistat—type 2 diabetes mellitus	0.000136	0.00054	CcSEcCtD
Darifenacin—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000136	0.00054	CcSEcCtD
Darifenacin—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000136	0.000538	CcSEcCtD
Darifenacin—Somnolence—Ramipril—type 2 diabetes mellitus	0.000136	0.000538	CcSEcCtD
Darifenacin—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.000134	0.000533	CcSEcCtD
Darifenacin—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000134	0.000531	CcSEcCtD
Darifenacin—Dizziness—Metformin—type 2 diabetes mellitus	0.000133	0.000526	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000132	0.000523	CcSEcCtD
Darifenacin—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000131	0.00052	CcSEcCtD
Darifenacin—Nausea—Valsartan—type 2 diabetes mellitus	0.000131	0.000518	CcSEcCtD
Darifenacin—Constipation—Ramipril—type 2 diabetes mellitus	0.000131	0.000518	CcSEcCtD
Darifenacin—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000129	0.000513	CcSEcCtD
Darifenacin—Nausea—Orlistat—type 2 diabetes mellitus	0.000129	0.000512	CcSEcCtD
Darifenacin—Asthenia—Losartan—type 2 diabetes mellitus	0.000128	0.000507	CcSEcCtD
Darifenacin—Vomiting—Metformin—type 2 diabetes mellitus	0.000127	0.000505	CcSEcCtD
Darifenacin—Rash—Metformin—type 2 diabetes mellitus	0.000126	0.000501	CcSEcCtD
Darifenacin—Dermatitis—Metformin—type 2 diabetes mellitus	0.000126	0.000501	CcSEcCtD
Darifenacin—Pruritus—Losartan—type 2 diabetes mellitus	0.000126	0.000499	CcSEcCtD
Darifenacin—Feeling abnormal—Ramipril—type 2 diabetes mellitus	0.000126	0.000499	CcSEcCtD
Darifenacin—Headache—Metformin—type 2 diabetes mellitus	0.000126	0.000498	CcSEcCtD
Darifenacin—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000125	0.000496	CcSEcCtD
Darifenacin—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	0.000125	0.000495	CcSEcCtD
Darifenacin—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000122	0.000483	CcSEcCtD
Darifenacin—Abdominal pain—Ramipril—type 2 diabetes mellitus	0.000121	0.000479	CcSEcCtD
Darifenacin—Vomiting—Irbesartan—type 2 diabetes mellitus	0.00012	0.000477	CcSEcCtD
Darifenacin—Rash—Irbesartan—type 2 diabetes mellitus	0.000119	0.000473	CcSEcCtD
Darifenacin—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000119	0.000473	CcSEcCtD
Darifenacin—Nausea—Metformin—type 2 diabetes mellitus	0.000119	0.000472	CcSEcCtD
Darifenacin—Headache—Irbesartan—type 2 diabetes mellitus	0.000119	0.00047	CcSEcCtD
Darifenacin—Dizziness—Losartan—type 2 diabetes mellitus	0.000118	0.000467	CcSEcCtD
Darifenacin—Vomiting—Losartan—type 2 diabetes mellitus	0.000113	0.000449	CcSEcCtD
Darifenacin—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.000112	0.000446	CcSEcCtD
Darifenacin—Nausea—Irbesartan—type 2 diabetes mellitus	0.000112	0.000446	CcSEcCtD
Darifenacin—Rash—Losartan—type 2 diabetes mellitus	0.000112	0.000445	CcSEcCtD
Darifenacin—Dermatitis—Losartan—type 2 diabetes mellitus	0.000112	0.000445	CcSEcCtD
Darifenacin—Headache—Losartan—type 2 diabetes mellitus	0.000112	0.000442	CcSEcCtD
Darifenacin—Asthenia—Ramipril—type 2 diabetes mellitus	0.00011	0.000434	CcSEcCtD
Darifenacin—Pruritus—Ramipril—type 2 diabetes mellitus	0.000108	0.000428	CcSEcCtD
Darifenacin—Nausea—Losartan—type 2 diabetes mellitus	0.000106	0.000419	CcSEcCtD
Darifenacin—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000104	0.000414	CcSEcCtD
Darifenacin—Methadone—CYP3A4—type 2 diabetes mellitus	0.000101	0.0333	CrCbGaD
Darifenacin—Dizziness—Ramipril—type 2 diabetes mellitus	0.000101	0.0004	CcSEcCtD
Darifenacin—Vomiting—Ramipril—type 2 diabetes mellitus	9.71e-05	0.000385	CcSEcCtD
Darifenacin—Rash—Ramipril—type 2 diabetes mellitus	9.63e-05	0.000382	CcSEcCtD
Darifenacin—Dermatitis—Ramipril—type 2 diabetes mellitus	9.62e-05	0.000381	CcSEcCtD
Darifenacin—Headache—Ramipril—type 2 diabetes mellitus	9.57e-05	0.000379	CcSEcCtD
Darifenacin—Nausea—Ramipril—type 2 diabetes mellitus	9.07e-05	0.00036	CcSEcCtD
Darifenacin—CHRM4—Signaling Pathways—CCL2—type 2 diabetes mellitus	9.56e-06	9.62e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—APOB—type 2 diabetes mellitus	9.55e-06	9.61e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	9.54e-06	9.6e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IGF1R—type 2 diabetes mellitus	9.51e-06	9.57e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—APOB—type 2 diabetes mellitus	9.46e-06	9.52e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EDN1—type 2 diabetes mellitus	9.43e-06	9.49e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IGF1R—type 2 diabetes mellitus	9.42e-06	9.48e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CTGF—type 2 diabetes mellitus	9.41e-06	9.47e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EDN1—type 2 diabetes mellitus	9.4e-06	9.46e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IGF1—type 2 diabetes mellitus	9.4e-06	9.45e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—AKT2—type 2 diabetes mellitus	9.39e-06	9.45e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—EGFR—type 2 diabetes mellitus	9.35e-06	9.41e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—AGT—type 2 diabetes mellitus	9.33e-06	9.39e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—HMGCR—type 2 diabetes mellitus	9.32e-06	9.38e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EDN1—type 2 diabetes mellitus	9.31e-06	9.36e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—INS—type 2 diabetes mellitus	9.3e-06	9.36e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—CALM1—type 2 diabetes mellitus	9.17e-06	9.23e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CCL2—type 2 diabetes mellitus	9.15e-06	9.21e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—LPL—type 2 diabetes mellitus	9.15e-06	9.2e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—APOE—type 2 diabetes mellitus	9.14e-06	9.2e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ADRA2A—type 2 diabetes mellitus	9.12e-06	9.18e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—LPL—type 2 diabetes mellitus	9.12e-06	9.18e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	9.1e-06	9.16e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—APOA1—type 2 diabetes mellitus	9.03e-06	9.09e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—LPL—type 2 diabetes mellitus	9.03e-06	9.09e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IGF1—type 2 diabetes mellitus	9e-06	9.05e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—AKT2—type 2 diabetes mellitus	8.99e-06	9.05e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	8.95e-06	9.01e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—EGFR—type 2 diabetes mellitus	8.95e-06	9.01e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—ADCY5—type 2 diabetes mellitus	8.93e-06	8.98e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	8.92e-06	8.98e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	8.84e-06	8.89e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	8.79e-06	8.85e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	8.79e-06	8.85e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	8.79e-06	8.85e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	8.79e-06	8.85e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	8.76e-06	8.82e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	8.67e-06	8.72e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	8.67e-06	8.72e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.58e-06	8.64e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.55e-06	8.61e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	8.54e-06	8.6e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—NOS3—type 2 diabetes mellitus	8.52e-06	8.57e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	8.52e-06	8.57e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.47e-06	8.52e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	8.45e-06	8.5e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	8.43e-06	8.48e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.43e-06	8.48e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.4e-06	8.45e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.32e-06	8.37e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	8.31e-06	8.36e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	8.31e-06	8.36e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—C3—type 2 diabetes mellitus	8.24e-06	8.29e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—C3—type 2 diabetes mellitus	8.21e-06	8.26e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	8.16e-06	8.21e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—NOS3—type 2 diabetes mellitus	8.16e-06	8.21e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—C3—type 2 diabetes mellitus	8.13e-06	8.18e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—RELA—type 2 diabetes mellitus	8.02e-06	8.07e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PPARG—type 2 diabetes mellitus	7.96e-06	8.01e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.85e-06	7.9e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	7.84e-06	7.89e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.83e-06	7.88e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.83e-06	7.88e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AGT—type 2 diabetes mellitus	7.82e-06	7.87e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.81e-06	7.86e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—INS—type 2 diabetes mellitus	7.81e-06	7.86e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AGT—type 2 diabetes mellitus	7.8e-06	7.85e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.75e-06	7.8e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.73e-06	7.78e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AGT—type 2 diabetes mellitus	7.72e-06	7.77e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.69e-06	7.74e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—RELA—type 2 diabetes mellitus	7.68e-06	7.73e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.67e-06	7.72e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—APOE—type 2 diabetes mellitus	7.67e-06	7.72e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—LEP—type 2 diabetes mellitus	7.67e-06	7.72e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—LEP—type 2 diabetes mellitus	7.64e-06	7.69e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—APOE—type 2 diabetes mellitus	7.64e-06	7.69e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.59e-06	7.64e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.58e-06	7.63e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—APOE—type 2 diabetes mellitus	7.57e-06	7.62e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—LEP—type 2 diabetes mellitus	7.57e-06	7.62e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.55e-06	7.6e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.48e-06	7.53e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	7.32e-06	7.36e-05	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	7.3e-06	7.35e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CASP3—type 2 diabetes mellitus	7.23e-06	7.28e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.23e-06	7.28e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.21e-06	7.25e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—IL6—type 2 diabetes mellitus	7.19e-06	7.23e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	7.17e-06	7.21e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	7.17e-06	7.21e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	7.16e-06	7.21e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	7.16e-06	7.21e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—ALB—type 2 diabetes mellitus	7.16e-06	7.2e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.14e-06	7.18e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	7.13e-06	7.17e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	7.03e-06	7.08e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	7.03e-06	7.07e-05	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	6.99e-06	7.03e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	6.99e-06	7.03e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	6.99e-06	7.03e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	6.99e-06	7.03e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	6.94e-06	6.99e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.93e-06	6.97e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—IL6—type 2 diabetes mellitus	6.88e-06	6.92e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3R1—type 2 diabetes mellitus	6.85e-06	6.89e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—NOS3—type 2 diabetes mellitus	6.85e-06	6.89e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.84e-06	6.88e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.83e-06	6.88e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	6.83e-06	6.87e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	6.82e-06	6.86e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.82e-06	6.86e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.76e-06	6.8e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.75e-06	6.79e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	6.74e-06	6.78e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	6.64e-06	6.68e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—AKT1—type 2 diabetes mellitus	6.63e-06	6.67e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—INS—type 2 diabetes mellitus	6.55e-06	6.59e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.54e-06	6.59e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—INS—type 2 diabetes mellitus	6.53e-06	6.57e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	6.52e-06	6.56e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.48e-06	6.52e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—INS—type 2 diabetes mellitus	6.47e-06	6.51e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.44e-06	6.48e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.42e-06	6.46e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	6.38e-06	6.42e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.36e-06	6.4e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	6.36e-06	6.4e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—AKT1—type 2 diabetes mellitus	6.35e-06	6.39e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.34e-06	6.38e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.33e-06	6.37e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.32e-06	6.35e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.31e-06	6.35e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.3e-06	6.34e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—SRC—type 2 diabetes mellitus	6.3e-06	6.34e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.28e-06	6.32e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	6.27e-06	6.3e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	6.27e-06	6.3e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	6.27e-06	6.3e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PTGS2—type 2 diabetes mellitus	6.26e-06	6.3e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.25e-06	6.29e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.25e-06	6.29e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.22e-06	6.26e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	6.19e-06	6.23e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	6.15e-06	6.19e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.14e-06	6.18e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	6.12e-06	6.16e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	6.09e-06	6.13e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—SRC—type 2 diabetes mellitus	6.03e-06	6.07e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.02e-06	6.05e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6e-06	6.03e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	5.96e-06	6e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.94e-06	5.98e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.88e-06	5.91e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	5.87e-06	5.91e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	5.76e-06	5.8e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.74e-06	5.78e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.74e-06	5.78e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	5.73e-06	5.77e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.73e-06	5.76e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.73e-06	5.76e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.67e-06	5.71e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.67e-06	5.71e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	5.67e-06	5.7e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	5.67e-06	5.7e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.63e-06	5.67e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	5.58e-06	5.61e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.52e-06	5.56e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	5.48e-06	5.52e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	5.46e-06	5.5e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	5.43e-06	5.47e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	5.43e-06	5.47e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	5.41e-06	5.44e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	5.4e-06	5.44e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.39e-06	5.43e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—RELA—type 2 diabetes mellitus	5.39e-06	5.42e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—RELA—type 2 diabetes mellitus	5.34e-06	5.37e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.29e-06	5.32e-05	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.92e-06	4.95e-05	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.91e-06	4.94e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.88e-06	4.91e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.86e-06	4.89e-05	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.86e-06	4.89e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.84e-06	4.88e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.83e-06	4.86e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.81e-06	4.84e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.78e-06	4.81e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	4.76e-06	4.79e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	4.68e-06	4.71e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.68e-06	4.71e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	4.67e-06	4.7e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	4.66e-06	4.69e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.61e-06	4.64e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	4.6e-06	4.63e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.59e-06	4.62e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.56e-06	4.59e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.55e-06	4.58e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.54e-06	4.57e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.5e-06	4.53e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.47e-06	4.5e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	4.46e-06	4.49e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.46e-06	4.48e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.41e-06	4.44e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	4.34e-06	4.37e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	4.28e-06	4.31e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	4.26e-06	4.29e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	4.25e-06	4.28e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IL6—type 2 diabetes mellitus	4.24e-06	4.27e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—SRC—type 2 diabetes mellitus	4.24e-06	4.26e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—SRC—type 2 diabetes mellitus	4.19e-06	4.22e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	4.17e-06	4.2e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	4.16e-06	4.18e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.14e-06	4.16e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.12e-06	4.15e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	4.09e-06	4.12e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	4.09e-06	4.12e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.08e-06	4.11e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IL6—type 2 diabetes mellitus	4.06e-06	4.09e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	4.05e-06	4.08e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	4e-06	4.02e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.92e-06	3.94e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	3.84e-06	3.86e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.8e-06	3.82e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.79e-06	3.81e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	3.77e-06	3.79e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.75e-06	3.77e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.75e-06	3.77e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	3.74e-06	3.77e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.72e-06	3.75e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.71e-06	3.74e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.68e-06	3.7e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	3.65e-06	3.67e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	3.59e-06	3.61e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	3.57e-06	3.6e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	3.53e-06	3.55e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—AKT1—type 2 diabetes mellitus	3.15e-06	3.17e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	3.11e-06	3.13e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	3.05e-06	3.07e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	2.86e-06	2.88e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL6—type 2 diabetes mellitus	2.85e-06	2.87e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL6—type 2 diabetes mellitus	2.83e-06	2.84e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	2.8e-06	2.82e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	2.68e-06	2.69e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	2.68e-06	2.69e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.64e-06	2.66e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.63e-06	2.65e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.61e-06	2.62e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	2.45e-06	2.46e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	1.88e-06	1.89e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.23e-06	1.24e-05	CbGpPWpGaD
